MPM BioImpact LLC — 13F Holdings & Portfolio

CIK 1687078 · latest 13F-HR filed 2026-08-14

MPM BioImpact LLC manages $1.64B in 13F-reported U.S. long-equity assets across 37 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are CGEM (10.81%), AKTS (9.50%), LQDA (6.74%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 7 new positions and exited 11; 20 existing positions rose in reported value and 10 fell.

AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.

Loading holdings…
AUM
$1.64B

Long-equity book

Holdings
37

Distinct positions

Period
2026-06-30

Filed 2026-08-14

Q/Q Activity
+7 / −11 / ↑20 / ↓10

vs 2026-03-31

Portfolio charts

Latest quarter's book, what changed, and how the portfolio has evolved across filings.

Portfolio map

Q2 26

Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.

Sector mix

% of 13F value

Sectors from each company's SIC code; funds and ETFs grouped separately.

Biggest buys and sells

Q1 26 → Q2 26

Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.

13F assets and positions

4 quarters

Total reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.

Top positions over time

reported value

The eight largest current positions, valued at each quarter end.

Concentration

top 10 = 55.3%

Cumulative share of the portfolio held in the largest N positions.

Firm Profile & Key People

Name Title / Status Ownership Type

Quarter-over-quarter changes

Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.

MPM BioImpact LLC Holdings (2026-06-30)

Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).

# Issuer Symbol CUSIP Value Weight Shares Type
1 Cullinan Therapeutics, Inc. CGEM 230031106 $177.2M 10.81% 9,731,341 SH
2 Aktis Oncology, Inc. AKTS 01021M104 $155.9M 9.50% 4,835,872 SH
3 Liquidia Corporation LQDA 53635D202 $110.5M 6.74% 1,386,174 SH
4 Revolution Medicines, Inc. RVMD 76155X100 $92.2M 5.62% 492,483 SH
5 Corcept Therapeutics, Inc. CORT 218352102 $67.0M 4.09% 771,028 SH
6 Edgewise Therapeutics Inc EWTX 28036F105 $65.9M 4.02% 1,620,780 SH
7 Travere Therapeutics Inc TVTX 89422G107 $63.8M 3.89% 1,122,731 SH
8 DBV Technologies S A DBVT 23306J309 $60.1M 3.67% 3,666,284 SH
9 Trevi Therapeutics Inc TRVI 89532M101 $57.3M 3.50% 3,073,577 SH
10 Alumis Inc ALMS 022307102 $56.8M 3.46% 2,019,020 SH
11 Uniqure NV QURE N90064101 $56.5M 3.44% 1,225,855 SH
12 Ultragenyx Pharmaceuticals, Inc. RARE 90400D108 $47.4M 2.89% 1,418,215 SH
13 Relay Therapeutics Inc. RLAY 75943R102 $45.2M 2.76% 2,415,672 SH
14 Abivax SA ABVX 00370M103 $44.8M 2.73% 336,347 SH
15 Dyne Therapeutics, Inc. DYN 26818M108 $42.7M 2.60% 1,922,093 SH
16 Dianthus Therapeutics Inc DNTH 252828108 $40.9M 2.50% 420,002 SH
17 BIOAGE Labs Inc BIOA 09077V100 $40.9M 2.49% 1,667,661 SH
18 Urogen Pharma Ltd URGN M96088105 $34.3M 2.09% 933,415 SH
19 MoonLake Immunotherapeutics MLTX 61559X104 $31.3M 1.91% 1,606,967 SH
20 Palvella Therapeutics Inc PVLA 697947109 $31.2M 1.90% 204,027 SH
21 Taysha Gene Therapies, Inc. TSHA 877619106 $30.6M 1.87% 4,500,000 SH
22 Syndax Pharmaceuticals Inc SNDX 87164F105 $29.2M 1.78% 1,333,523 SH
23 Monte Rosa Therapeutics Inc GLUE 61225M102 $28.1M 1.71% 1,161,081 SH
24 Zura Bio Ltd. ZURA G9TY5A101 $26.4M 1.61% 4,472,843 SH
25 Natera Inc NTRA 632307104 $25.1M 1.53% 92,638 SH
26 Stoke Therapeutics Inc STOK 86150R107 $23.7M 1.44% 723,314 SH
27 Adlai Nortye Ltd ANL 00704R109 $22.3M 1.36% 1,936,291 SH
28 Belite Bio Inc BLTE 07782B104 $21.1M 1.29% 137,208 SH
29 Forte Biosciences, Inc. FBRX 34962G208 $21.0M 1.28% 987,448 SH
30 Oric Pharmaceuticals Inc ORIC 68622P109 $20.4M 1.24% 1,882,162 SH
31 Tarsus Pharmaceuticals Inc TARS 87650L103 $20.3M 1.24% 322,007 SH
32 Annexon Inc ANNX 03589W102 $20.2M 1.23% 3,544,354 SH
33 Bright Minds Biosciences Inc DRUG 10919W405 $14.2M 0.87% 202,114 SH
34 Entrada Therapeutics, Inc. TRDA 29384C108 $9.2M 0.56% 1,253,053 SH
35 Aclaris Therapeutics Inc ACRS 00461U105 $5.5M 0.34% 1,042,467 SH
36 Context Therapeutics Inc CNTX 21077P108 $719.5K 0.04% 1,299,046 SH
37 Werewolf Therapeutics, Inc. HOWL 95075A107 $28.9K 0.00% 80,142 SH
Filing History
Period Filed AUM Holdings Accession
2026-06-30 2026-08-14 $1.64B 37 0001193125-26-352199
2026-03-31 2026-05-15 $1.29B 41 0001193125-26-226995
2025-12-31 2026-02-17 $874.0M 38 0001193125-26-054813
2025-09-30 2025-11-14 $610.9M 40 0001193125-25-283112
Filer Information
Address
399 BOYLSTON STREET, SUITE 1100
BOSTON, MA 02116
Phone
(617) 425-9200
Filing Manager
MPM BIOIMPACT LLC
BOSTON, MA
Signatory
Christopher Wolf
Chief Financial Officer